What it sells
World model for human cells (drug discovery)
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D leaders at pharma and biotech.
Trigger: what makes them buy now?
Cell response to treatment is largely unpredictable; existing cell data is observational, static and context-poor.
Workflow: what inputs become what output?
Lab-in-the-loop: the model chooses experiments, the platform runs them at scale, each result improves predictions and guides the next experiment.
Distribution: how it reaches customers
Partnership-led (Partner with us, Get in touch).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-13 | Seed | €22M | — | news.google.com |
| 2026-10-07 | Seed | $25M | — | sifted.eu |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.